Hope for Hemophilia

UNC’s legacy of hemophilia treatment continues with new gene therapy

Brent Harrison stands on a beach

UNC’s legacy of hemophilia treatment continues with new gene therapy

Hemophilia is a genetic blood-clotting disorder that affects 400,000 people worldwide. It often leads to spontaneous bleeds in soft tissue, like muscles or joints. If a bleed is bad enough, a joint might swell to the size of a watermelon.

Brent Harrison has spent most of his life infusing himself intravenously with a clotting factor three times a week. In 2018, he began participating in a clinical trial at UNC-Chapel Hill for a gene therapy treatment from pharmaceutical company BioMarin.

Harrison received one four-hour infusion of the medication — and hasn’t had a bleed or any infusions since. That was nearly four years ago.

Harrison is one of 134 people from across the globe who participated in the BioMarin clinical trial — the largest-ever Phase 3 gene therapy study for adults with severe hemophilia A. If the company receives FDA approval for the treatment, it will be the first hemophilia gene therapy to ever be licensed.

“Gene therapy has had a huge effect on these patients,” says Nigel Key, Harold R. Roberts Distinguished Professor in the Department of Medicine, leader of the BioMarin clinical trial at UNC and director of the UNC Blood Research Center. “It’s changing people’s lives.”

Before the 1960s, the average lifespan of a person with hemophilia was 11 years. Today, that number has increased to 68. This is partly due to the work of UNC researchers who have dedicated their lives to the disorder, unpacking how it occurs, developing treatments and creating drug-delivery systems that could lead to a potential cure.

Learn more about UNC’s history of hemophilia research…Opens in new window

UNC School of Medicine Funding Priorities

Readers Also Viewed...

Michelle Itano works with microscopes in a lab
Faculty Support

Maestro of Microscopy

New microscopy technology allows scientists to pull more data from samples than ever before

Amy Loftis stands in a lab

Prioritizing Care in a Pandemic

Massey Distinguished Service Award recognizes Loftis’ contributions to Carolina Testing Together Program

Sleeping baby prior to MRI. (CIDD at UNC-CH)

Effects of Amygdala Overgrowth

Scientists identify overgrowth of key brain structure in babies who later develop autism

Jamiel and Shayne Owens smiling at each other on a city sidewalk

Bringing Autism Fathers Together

The UNC Autism Research Center is hosting the Autism Fathers Conference to help fathers find information, resources and community.

Right, βII-spectrin (magenta) forms aggregates throughout neurites of a mouse cortical neuron expressing one of the human SPTBN1 variants. (Lorenzo Lab)

Discoveries of SPTBN1 Variant

New developments in neuroscience research that potentially impact the formation of new neurological disorders

Christina hugging her grandfather who is sitting

Get Real & Heel

Expanding an exercise program for cancer survivors